1. Exploration of the 2,3-dihydroisoindole pharmacophore for inhibition of the influenza virus PA endonuclease
- Author
-
Rogolino, Dominga, Naesens, Lieve, Bartoli, Jennifer, Carcelli, Mauro, De Luca, Laura, Pelosi, Giorgio, Stokes, Ryjul W, Van Berwaer, Ria, Vittorio, Serena, Stevaert, Annelies, and Cohen, Seth M
- Subjects
Medicinal and Biomolecular Chemistry ,Chemical Sciences ,Pneumonia & Influenza ,Influenza ,Infectious Diseases ,Prevention ,Emerging Infectious Diseases ,Vaccine Related ,Biodefense ,2.2 Factors relating to the physical environment ,Aetiology ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Infection ,Antiviral Agents ,Dose-Response Relationship ,Drug ,Enzyme Inhibitors ,HEK293 Cells ,Humans ,Isoindoles ,Molecular Docking Simulation ,Molecular Structure ,Orthomyxoviridae ,RNA-Dependent RNA Polymerase ,Structure-Activity Relationship ,Viral Proteins ,Influenza virus ,Endonuclease ,Antiviral ,Isoindolinone ,Metal-binding pharmacophore ,Organic Chemistry ,Medicinal and biomolecular chemistry ,Organic chemistry - Abstract
Seasonal influenza A and B viruses represent a global concern. Antiviral drugs are crucial to treat severe influenza in high-risk patients and prevent virus spread in case of a pandemic. The emergence of viruses showing drug resistance, in particular for the recently licensed polymerase inhibitor baloxavir marboxil, drives the need for developing alternative antivirals. The endonuclease activity residing in the N-terminal domain of the polymerase acidic protein (PAN) is crucial for viral RNA synthesis and a validated target for drug design. Its function can be impaired by molecules bearing a metal-binding pharmacophore (MBP) able to coordinate the two divalent metal ions in the active site. In the present work, the 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one scaffold is explored for the inhibition of influenza virus PA endonuclease. The structure-activity relationship was analysed by modifying the substituents on the lipophilic moiety linked to the MBP. The new compounds exhibited nanomolar inhibitory activity in a FRET-based enzymatic assay, and a few compounds (15-17, 21) offered inhibition in the micromolar range, in a cell-based influenza virus polymerase assay. When investigated against a panel of PA-mutant forms, compound 17 was shown to retain full activity against the baloxavir-resistant I38T mutant. This was corroborated by docking studies providing insight into the binding mode of this novel class of PA inhibitors.
- Published
- 2021